文献速递肿瘤 PET/CT

FDG PET/CT作预后评估为何需谐调:EARL合规SUVmax是非小细胞肺癌独立预后因素

Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-14

单中心回顾性研究纳入139例IIIA-IIIB期非小细胞肺癌患者,按EANM指南采集PET数据并行PSF重建,再经6.3 mm高斯滤波达EARL标准。EARL合规数据集最优SUVmax截断值为8.47(95%CI 7.23-9.31),与肺癌死亡独立相关(HR 1.92,95%CI 1.16-3.19);将PSF或EARL截断值交叉应用或用于模拟多中心非谐调数据时,SUVmax与肺癌死亡的关联不再显著。

要点

  • EARL合规数据集最优SUVmax截断值为8.47(95%CI 7.23-9.31),与肺癌死亡独立相关(HR 1.92,95%CI 1.16-3.19)。
  • 未滤波PSF数据集最优SUVmax截断值为25.43(95%CI 23.41-26.31),与肺癌死亡独立相关(HR 1.73,95%CI 1.05-2.84)。
  • 将PSF或EARL截断值交叉应用或用于模拟多中心非谐调数据时,SUVmax与肺癌死亡的关联不再显著。

核心结论

  • 本研究为晚期非小细胞肺癌提供EARL合规的SUVmax作为独立预后因素,作者指出该结果需在更大队列中确认,理想情况是在其他EARL认证中心确认。
  • 作者强调将PET定量指标用于患者风险分层时需进行谐调。

研究设计与样本

  • 单中心回顾性研究,连续纳入139例IIIA-IIIB期非小细胞肺癌患者。
  • PET数据按EANM指南采集,采用未滤波点扩散函数(PSF)重建;随后用EQ.PET方法施加6.3 mm高斯滤波以达到EANM/EARL谐调标准(PSFEARL)。
  • 通过随机创建四组分别以未滤波PSF及3 mm、5 mm、10 mm高斯后滤波PSF重建图像的患者,模拟包含非EARL合规系统的多中心研究。
  • 最优SUV截断值通过两折交叉验证确定,将总样本分为学习与验证子样本;采用比例Cox风险模型估计年龄调整和多变量调整的风险比(HR)及95%置信区间,Kaplan-Meier曲线用log rank检验比较。

主要发现

  • 中位随访28个月(1-104个月);全人群36个月总生存率估计为0.39(95%CI 0.31-0.47)。
  • PSF数据集最优SUVmax截断值为25.43(95%CI 23.41-26.31),EARL合规数据集为8.47(95%CI 7.23-9.31)。
  • 上述SUVmax截断值均与肺癌死亡显著且独立相关,PSF数据集HR为1.73(95%CI 1.05-2.84),EARL合规数据集HR为1.92(95%CI 1.16-3.19)。
  • 将PSF最优SUVmax截断值应用于EARL合规数据集、将EARL最优SUVmax截断值应用于PSF数据集,或将EARL合规最优SUVmax截断值应用于模拟多中心数据集时,肿瘤SUVmax与肺癌死亡的关联不再显著。

关键数值与推荐

  • EARL合规数据集最优SUVmax截断值8.47(95%CI 7.23-9.31),与肺癌死亡独立相关(HR 1.92,95%CI 1.16-3.19)。
  • PSF数据集最优SUVmax截断值25.43(95%CI 23.41-26.31),与肺癌死亡独立相关(HR 1.73,95%CI 1.05-2.84)。
  • 全人群36个月总生存率估计为0.39(95%CI 0.31-0.47)。

临床怎么用

  • 原文结论指出,本研究为PET界提供了EARL合规的SUVmax作为晚期非小细胞肺癌的独立预后因素,该结果需在更大队列中确认,理想情况是在其他EARL认证中心确认。
  • 原文结论强调,将PET定量指标用于患者风险分层时需进行谐调。

局限性

  • 原文结论指出该结果需在更大队列中确认,理想情况是在其他EARL认证中心确认。
  • 本研究为单中心回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To determine EARL-compliant prognostic SUV thresholds in a mature cohort of patients with locally advanced NSCLC, and to demonstrate how detrimental it is to use a threshold determined on an older-generation PET system with a newer PET/CT machine, and vice versa, or to use such a threshold with non-harmonized multicentre pooled data. MATERIALS AND METHODS: This was a single-centre retrospective study including 139 consecutive stage IIIA-IIIB patients. PET data were acquired as per the EANM guidelines and reconstructed with unfiltered point spread function (PSF) reconstruction. Subsequently, a 6.3 mm Gaussian filter was applied using the EQ.PET (Siemens Healthineers) methodology to meet the EANM/EARL harmonizing standards (PSFEARL). A multicentre study including non-EARL-compliant systems was simulated by randomly creating four groups of patients whose images were reconstructed with unfiltered PSF and PSF with Gaussian post-filtering of 3, 5, and 10 mm. Identification of optimal SUV thresholds was based on a two-fold cross-validation process that partitioned the overall sample into learning and validation subsamples. Proportional Cox hazards models were used to estimate age-adjusted and multivariable-adjusted hazard ratios (HRs) and their 95% confidence intervals. Kaplan-Meier curves were compared using the log rank test. RESULTS: Median follow-up was 28 months (1-104 months). For the whole population, the estimated overall survival rate at 36 months was 0.39 [0.31-0.47]. The optimal SUVmax cutoff value was 25.43 (95% CI: 23.41-26.31) and 8.47 (95% CI: 7.23-9.31) for the PSF and for the EARL-compliant dataset respectively. These SUVmax cutoff values were both significantly and independently associated with lung cancer mortality; HRs were 1.73 (1.05-2.84) and 1.92 (1.16-3.19) for the PSF and the EARL-compliant dataset respectively. When (i) applying the optimal PSF SUVmax cutoff on an EARL-compliant dataset and the optimal EARL SUVmax cutoff on a PSF dataset or (ii) applying the optimal EARL compliant SUVmax cutoff to a simulated multicentre dataset, the tumour SUVmax was no longer significantly associated with lung cancer mortality. CONCLUSION: The present study provides the PET community with an EARL-compliant SUVmax as an independent prognosticator for advanced NSCLC that should be confirmed in a larger cohort, ideally at other EARL accredited centres, and highlights the need to harmonize PET quantitative metrics when using them for risk stratification of patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Houdu B, Lasnon C, Licaj I, et al. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30218317. doi:10.1007/s00259-018-4151-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。